Date: 2011-02-10
Type of information: Initiation of preclinical development
phase: 1a
Announcement: initiation of the study
Company: Medivir (Sweden)
Product: TMC649128
Action
mechanism: TMC649128 is a nucleoside NS5B polymerase inhibitor. The drug is being developed in collaboration with Tibotec Pharmaceuticals.
Disease: chronic hepatitis C virus infection
Therapeutic area: Infectious diseases
Country: Belgium
Trial
details: The phase 1a trial is a double-blind, randomized, placebo-controlled single-ascending dose trial to assess the safety, tolerability and pharmacokinetics in healthy volunteers and will be conducted in Belgium.
Latest
news: Medivir entered a R&D agreement in the field of hepatitis C virus polymerase with Ortho Biotech Products LP, an affiliate of Tibotec in May 2008. The development of TMC649128 falls under this agreement and by entering clinical development, a milestone payment of € 7 million has been triggered for payment to Medivir.
